Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Key companies in Japan’s melanoma market need to establish stronger digital support across all channels, finds GlobalData

The melanoma therapeutics market in Japan comprises of drugs approved for chemotherapy, immunotherapy, and targeted therapy. Among these, immunotherapy and targeted therapy are the leading class of drugs. The digital support from existing players available for patients through branded and unbranded channels is not equally distributed as there is a lack of presence or weaker […]
Read more

J&J’s COVID-19 vaccine best used to control outbreak, while Novavax’s vaccine is better for overall protection, says GlobalData

Following the news that Novavax’s COVID-19 vaccine shows 89.3% while Johnson & Johnson’s (J&J) demonstrated 66% efficacy; Michael Breen, PhD, Director of Infectious Diseases and Ophthalmology and Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offer their view: “J&J’s COVID-19 vaccine will be the agent of choice for […]
Read more

Across pharmaceutical value chain drug development process will experience biggest impact from COVID-19 in 2021

Despite seriously affecting the ability to carry out clinical research, COVID-19 is also proving to be a catalyst that may transform the drug development process, with technological innovations taking center stage in driving this change, says GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘The State of the Biopharmaceutical Industry 2021’, reveals that the drug development process will face the biggest impact from COVID-19 in 2021, as confirmed by 32% (N=63) out of 198 pharmaceutical industry professionals. […]
Read more

Xeljanz safety data in Rheumatoid Arthritis could mean headaches for all JAK inhibitors

Following Pfizer’s recent announcement of co-primary endpoint results from ORAL Surveillance (NCT02092467) in rheumatoid arthritis (RA) patients with cardiovascular (CV) risk factors; Rose Joachim, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “These results signal troubles ahead for Xeljanz and potentially other JAK inhibitor products. The ORAL Surveillance trial first came under scrutiny in early 2019, when Pfizer had to modify the protocol […]
Read more

Telemedicine expected to be a leading industry trend in 2021, with some telemedicine apps having reported whopping 8,270% increase in downloads in 2020, says GlobalData

The COVID-19 pandemic has shown the many wide-ranging benefits of telemedicine. In a survey by GlobalData, pharmaceutical industry professionals noted that they expect telemedicine to remain a leading industry trend in 2021 and beyond. GlobalData’s latest report, The State of the Biopharmaceutical Industry 2021, reveals that telemedicine is expected to be a leading industry trend […]
Read more

Misinformation and future of work among several key trends to watch out for in pharmaceutical industry in 2021

The pharmaceutical industry will be shaped by several emerging trends in 2021. The industry will need to adapt quickly post-COVID-19 by overcoming the spread of online misinformation and preparing for a new way of working, says GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘The State of the Biopharmaceutical Industry 2021’, identified several […]
Read more

Nearly one-third of phase III clinical trials for cervical cancer are expected to conclude in 2021, says GlobalData

This year is expected to provide significant insights into the future of cervical cancer treatment since out of the 107 ongoing clinical trials worldwide for cervical cancer, 30% are estimated to be completed by the end of the year, says GlobalData, a leading data and analytics company. Miguel Ferreira, MSc, Oncology and Hematology Analyst at GlobalData, comments: “Cervical cancer is the eighth most common cancer worldwide and one of the most treatable and preventable types of cancer, given that up to 99% of cases are linked to infection with the high-risk variants of the sexually-transmitted human papillomavirus (HPV). For Cervical Cancer Awareness […]
Read more

Forxiga’s priority review and breakthrough designation highlight potential to differentiate in CKD space, says GlobalData

Forxiga’s (dapagliflozin) latest priority review by the FDA for chronic kidney disease (CKD) further signifies the drug’s major advantages over existing treatments and will provide enhanced support for its development in targeting reduced glomerular filtration rate (GFR) and all-cause death. If approved, Forxiga will likely be used as a novel standard of care (SoC) option […]
Read more

Phase II trial of anti-amyloid AR1001 signals little promise for patients with Alzheimer’s disease, says GlobalData

Following the news that AriBio announced the completion of a Phase II clinical trial of AR1001; Sarah Elsayed, MBA, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Given the complexity in developing disease-modifying treatments (DMTs) in the Alzheimer’s Disease (AD) market, coupled with the high rate of late-stage clinical trial […]
Read more

Artificial intelligence will be most disruptive technology across pharmaceutical industry in 2021 and beyond

Artificial intelligence (AI) will transform the pharmaceutical industry in the coming years by delivering productivity improvements and efficiencies across the entire pharma value chain, says GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘The State of the Biopharmaceutical Industry 2021’, reveals that AI is expected to be the emerging technology that will have […]
Read more

Myovant/Pfizer Collaboration to boost Relugolix potential in female health space, intensify competition among rivals, says GlobalData

Myovant Sciences’ deal with Pfizer to co-develop and commercialize oral GnRH antagonist relugolix in oncology and women’s health in the US and Canada will substantially boost the relugolix franchise and intensify competition in the female health space, according to GlobalData, a leading data and analytics company. Kelly Lambrinos, Managing Analyst at GlobalData comments: “Key players AbbVie, Myovant and […]
Read more

Preliminary results from Aldeyra’s Phase III Tranquility trial offer promise for patients with dry eye syndrome

Aldeyra Therapeutics recently announced top-line results from the run-in cohort of the Phase III trial evaluating its product 0.25% reproxalap for patients with dry eye syndrome (DES). The positive impact of the therapy on endpoints, such as ocular dryness, discomfort and Schirmer’s test, although preliminary, signals an important advancement for DES patients compared to currently […]
Read more

REMD-477 top line results highlight the benefits of adjunct therapies in Type 1 Diabetes

REMD Biotherapeutics recently announced the top-line results of its Phase II study of volagidemab, which aimed to determine whether volagidemab could decrease daily insulin requirements and improve glycemic control in Type 1 Diabetes (T1D patients). These results show the promise of adjunct therapeutics, as their potential impacts on lowering blood glucose levels, reducing patient insulin […]
Read more

Remote patient monitoring will continue to transform healthcare delivery and clinical trials in 2021

Ongoing COVID-19 lockdowns and requirements of social distancing have swiftly pushed healthcare provision and patient monitoring towards remote options. Even though remote patient monitoring (RPM) was already being used before the start of the pandemic, the uptake of the technology was relatively low, primarily used to ensure better post-acute care and management of chronic conditions, such as diabetes. However, […]
Read more

Late-stage growth hormone deficiency pipeline addresses unmet needs for patient convenience and treatment compliance

The Food and Drug Administration (FDA) recently accepted Pfizer and OPKO Biologics Biologics License Application (BLA) for somatrogon for the treatment of pediatric growth hormone deficiency (GHD). Somatrogon belongs to a new class of long-acting growth hormones (GH) that are projected to steal substantial market share from the current leading GHD therapeutics, says GlobalData, a […]
Read more
1 … 70 71 72 73 74 … 108